News

News

May 10, 2017

IMMUNOMEDICS ANNOUNCES THIRD QUARTER FISCAL 2017 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

May 10, 2017

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR THIRD QUARTER FISCAL 2017 RESULTS

May 5, 2017

IMMUNOMEDICS DELIVERS BUSINESS UPDATES, ANNOUNCES PRIVATE PLACEMENT OFFERING AND OUTLINES STRATEGIC STEPS TO DRIVE STOCKHOLDER VALUE

April 5, 2017

IMMUNOMEDICS REPORTS SACITUZUMAB GOVITECAN (IMMU-132) IS ACTIVE IN PATIENTS WITH METASTATIC SMALL-CELL LUNG CANCER WHO ARE SENSITIVE OR RESISTANT TO FIRST-LINE CHEMOTHERAPY

April 4, 2017

IMMUNOMEDICS PRESENTS PRECLINICAL STUDY THAT DEMONSTRATES INCREASED SN-38 DELIVERY WITH LABETUZUMAB GOVITECAN (IMMU-130) COMPARED WITH IRINOTECAN

April 4, 2017

IMMUNOMEDICS REPORTS SACITUZUMAB GOVITECAN (IMMU-132) DELIVERS HIGH LEVELS OF SN-38 THAT OVERCOME CHEMORESISTANT TUMORS WITH MODERATE TO STRONG TROP-2 EXPRESSION

March 15, 2017

IMMUNOMEDICS ANNOUNCES PUBLICATION OF RESULTS IN JOURNAL OF CLINICAL ONCOLOGY, DEMONSTRATING TREATMENT WITH SACITUZUMAB GOVITECAN (IMMU-132) PRODUCES EARLY AND DURABLE RESPONSES IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER

March 3, 2017

IMMUNOMEDICS BOARD INSTITUTES MEASURES AS STOCKHOLDER FIDUCIARIES TO PRESERVE THEIR BEST BUSINESS JUDGEMENT TO PROTECT THE RIGHTS OF ALL STOCKHOLDERS

March 2, 2017

IMMUNOMEDICS OUTLINES REVISED SETTLEMENT OFFER REJECTED BY VENBIO; ANNOUNCES ACTIONS THAT ARE IN THE BEST INTERESTS OF ALL STOCKHOLDERS

February 28, 2017

IMMUNOMEDICS TO PRESENT AT COWEN AND COMPANY 37TH ANNUAL HEALTH CARE CONFERENCE

February 27, 2017

IMMUNOMEDICS ISSUES OPEN LETTER HIGHLIGHTING THE CLEAR DECISION TO VOTE FOR IMMUNOMEDICS TO ENSURE CONTINUED VALUE CREATION

February 23, 2017

IMMUNOMEDICS ANNOUNCES COMPANY’S IMMUNE CHECKPOINT INHIBITOR ENHANCES ANTI-TUMOR POTENCY OF T-CELL-REDIRECTING BISPECIFIC ANTIBODIES

February 21, 2017

IMMUNOMEDICS FILES FEDERAL LAWSUIT AGAINST VENBIO FOR CONTINUING MATERIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS

February 17, 2017

IMMUNOMEDICS PRESENTS UPDATED RESULTS WITH SACITUZUMAB GOVITECAN (IMMU-132) IN HEAVILY-PRETREATED PATIENTS WITH METASTATIC UROTHELIAL CANCER

February 15, 2017

IMMUNOMEDICS SENDS LETTER TO STOCKHOLDERS HIGHLIGHTING VALUE CREATING GLOBAL LICENSING AGREEMENT, UNDERSCORING FULFILLMENT OF PROMISE TO STOCKHOLDERS

February 14, 2017

IMMUNOMEDICS COMMENTS ON BASELESS VENBIO LAWSUIT

February 10, 2017

IMMUNOMEDICS ANNOUNCES POSTPONEMENT OF 2016 ANNUAL MEETING

February 10, 2017

Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties

February 9, 2017

IMMUNOMEDICS ANNOUNCES SECOND QUARTER FISCAL 2017 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

February 9, 2017

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR SECOND QUARTER FISCAL 2017 RESULTS

February 7, 2017

IMMUNOMEDICS STRONGLY ENCOURAGES STOCKHOLDERS TO REJECT THE VENBIO NOMINEES — WITH FOUR NEW INDEPENDENT DIRECTORS AND A ROBUST VALUE-MAXIMIZATION PROCESS, STOCKHOLDERS SHOULD NOT RISK GIVING VENBIO DIRECTORS CONTROL OF THE IMMUNOMEDICS BOARD OF DIRECTORS

February 2, 2017

IMMUNOMEDICS MAILS LETTER TO STOCKHOLDERS HIGHLIGHTING STRENGTH OF NEW BOARD AND DEEP ENGAGEMENT IN ROBUST, VALUE-CREATING STRATEGIC AND CMC PROCESSES

January 30, 2017

IMMUNOMEDICS SETS THE RECORD STRAIGHT IN NEW PRESENTATION

January 27, 2017

IMMUNOMEDICS ISSUES STATEMENT TO STOCKHOLDERS AND FILES INVESTOR PRESENTATION

January 24, 2017

IMMUNOMEDICS MAILS LETTER TO STOCKHOLDERS

January 18, 2017

IMMUNOMEDICS HIGHLIGHTS EXPANDED PIPELINE POSITIONING COMPANY FOR SUSTAINED VALUE CREATION

January 18, 2017

IMMUNOMEDICS ANNOUNCES NEW DATA FOR IMMU-132 AT INVESTOR R&D DAY

January 12, 2017

IMMUNOMEDICS TO MAIL LETTER TO STOCKHOLDERS HIGHLIGHTING UNPRECEDENTED PROGRESS TOWARD ENHANCED VALUE CREATION

January 9, 2017

IMMUNOMEDICS ANNOUNCES ANTITUMOR EFFECT OF SACITUZUMAB GOVITECAN (IMMU-132) IN TRIPLE-NEGATIVE BREAST CANCER CAN BE ENHANCED WITH DNA-REPAIR INHIBITORS

January 9, 2017

IMMUNOMEDICS ANNOUNCES RECONSTITUTED BOARD OF DIRECTORS AND LEADERSHIP SUCCESSION PLAN

January 5, 2017

IMMUNOMEDICS ANNOUNCES INVESTOR R&D DAY ON JANUARY 18, 2017